Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
- PMID: 33106386
- PMCID: PMC7592253
- DOI: 10.1136/jitc-2020-000537
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
Abstract
Background: Despite some successes with checkpoint inhibitors for treating cancer, most patients remain refractory to treatment, possibly due to the inhibitory nature of the tumor stroma that impedes the function and entry of effector cells. We devised a new technique of combining immunotherapy with radiotherapy (XRT), more specifically low-dose XRT, to overcome the stroma and maximize systemic outcomes.
Methods: We bilaterally established 344SQ lung adenocarcinoma tumors in 129Sv/Ev mice. Primary and secondary tumors were irradiated with either high-dose or low-dose of XRT with systemic anti-programmed cell death protein 1 and anti-cytotoxic T-lymphocyte associated protein 4 administration. Survival and tumor growth were monitored for the various groups, and secondary tumors were phenotyped by flow cytometry for immune populations. Tumor growth factor-beta (TGF-β) cytokine levels were assessed locally after low-dose XRT, and specific immune-cell depletion experiments were conducted to identify the major contributors to the observed systemic antitumor effect.
Results: Through our preclinical and clinical studies, we observed that when tumor burden was high, there was a necessity of combining high-dose XRT to 'prime' T cells at the primary tumor site, with low-dose XRT directed to secondary (metastatic) tumors to 'modulate the stroma'. Low-dose XRT improved the antitumor outcomes of checkpoint inhibitors by favoring M1 macrophage polarization, enhancing natural killer (NK) cell infiltration, and reducing TGF-β levels. Depletion of CD4+ T cells and NK cells abrogated the observed antitumor effect.
Conclusion: Our data extend the benefits of low-dose XRT to reprogram the tumor environment and improve the infiltration and function of effector immune cells into secondary tumors.
Keywords: immunotherapy; lung neoplasms; radioimmunotherapy; radiotherapy; tumor microenvironment.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: JW serves on the science advisory boards for Alpine Immune Sciences, RefleXion Medical, Mavu Pharma, MolecularMatch and Checkmate Pharmaceuticals, and he is the founder of Healios Oncology, MolecularMatch, and OncoResponse companies. MD Anderson Cancer Center has a trademark for RadScopal (TM). JW has research support collaborations with Bristol Myers Squibb, Checkmate Pharmaceuticals, Mavu pharma, Merck, and Nanobiotix. AD is an advisory board member for Nektar Therapeutics. IG is a consultant for Bristol Myers Squibb and Array Biopharma. DSH has consulting/advisory role in Alpha Insights, Axiom, Adaptimmune, Baxter, Bayer, Genentech, GLG, Group H, Guidepoint Global, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Seattle Genetics, Takeda, Trieza Therapeutics. DSH has research/grant funding from AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, MiRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda. DSH's ownership interests include MolecularMatch (Advisor), OncoResponse (founder), Presagia Inc (Advisor).
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7592253/bin/jitc-2020-000537f01.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7592253/bin/jitc-2020-000537f02.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7592253/bin/jitc-2020-000537f03.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7592253/bin/jitc-2020-000537f04.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7592253/bin/jitc-2020-000537f05.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7592253/bin/jitc-2020-000537f06.gif)
Similar articles
-
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory.Front Immunol. 2022 Oct 6;13:984318. doi: 10.3389/fimmu.2022.984318. eCollection 2022. Front Immunol. 2022. PMID: 36275767 Free PMC article.
-
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.J Immunother Cancer. 2020 Jun;8(1):e000289. doi: 10.1136/jitc-2019-000289. J Immunother Cancer. 2020. PMID: 32581056 Free PMC article.
-
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.Cancer Immunol Res. 2015 Apr;3(4):345-55. doi: 10.1158/2326-6066.CIR-14-0196. Epub 2014 Dec 19. Cancer Immunol Res. 2015. PMID: 25527358 Free PMC article.
-
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.Front Immunol. 2019 Feb 15;10:193. doi: 10.3389/fimmu.2019.00193. eCollection 2019. Front Immunol. 2019. PMID: 30828330 Free PMC article. Review.
-
Combination of radiotherapy and immune checkpoint inhibitors.Semin Radiat Oncol. 2015 Jan;25(1):28-33. doi: 10.1016/j.semradonc.2014.07.004. Semin Radiat Oncol. 2015. PMID: 25481263 Review.
Cited by
-
Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.Front Immunol. 2024 Feb 21;15:1357101. doi: 10.3389/fimmu.2024.1357101. eCollection 2024. Front Immunol. 2024. PMID: 38449871 Free PMC article. Review.
-
Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.Heliyon. 2024 Feb 27;10(5):e27103. doi: 10.1016/j.heliyon.2024.e27103. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38449655 Free PMC article.
-
Fluorescence and immune-cell infiltration of nonneoplastic, postbrachytherapy brain tissue in 5-ALA-guided resection of recurrent anaplastic meningioma: illustrative case.J Neurosurg Case Lessons. 2024 Feb 26;7(9):CASE23550. doi: 10.3171/CASE23550. Print 2024 Feb 26. J Neurosurg Case Lessons. 2024. PMID: 38408351 Free PMC article.
-
Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma.Front Immunol. 2024 Jan 8;14:1334408. doi: 10.3389/fimmu.2023.1334408. eCollection 2023. Front Immunol. 2024. PMID: 38259481 Free PMC article.
-
The Correlation Between Low-Dose Radiotherapy Area of the Mediastinum and CD8+T Cells and the Efficacy of Radiotherapy for Non-Small Cell Lung Cancer.Cancer Manag Res. 2024 Jan 12;16:23-35. doi: 10.2147/CMAR.S438440. eCollection 2024. Cancer Manag Res. 2024. PMID: 38230351 Free PMC article.
References
-
- Demaria S, Kawashima N, Yang AM, et al. . Immune-Mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728–34. - PubMed
-
- Gomez DR, Blumenschein GR, Lee JJ, et al. . Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17:1672–82. 10.1016/S1470-2045(16)30532-0 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials